IDEAYA Biosciences (IDYA) Projected to Post Earnings on Tuesday

IDEAYA Biosciences (NASDAQ:IDYA) is projected to post its quarterly earnings results before the market opens on Tuesday, February 18th. Analysts expect IDEAYA Biosciences to post earnings of ($0.63) per share and revenue of $4.31 million for the quarter.

IDEAYA Biosciences Trading Down 2.5 %

Shares of IDYA opened at $22.42 on Tuesday. The company has a 50-day moving average of $24.94 and a two-hundred day moving average of $30.52. The stock has a market cap of $1.94 billion, a P/E ratio of -9.62 and a beta of 0.82. IDEAYA Biosciences has a 12-month low of $22.10 and a 12-month high of $47.74.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on IDYA shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of IDEAYA Biosciences in a research note on Monday, January 13th. Leerink Partners lowered IDEAYA Biosciences from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $41.00 to $27.00 in a research note on Tuesday, November 5th. Royal Bank of Canada reissued an “outperform” rating and issued a $61.00 target price on shares of IDEAYA Biosciences in a research note on Wednesday, January 15th. Leerink Partnrs cut shares of IDEAYA Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 5th. Finally, UBS Group initiated coverage on shares of IDEAYA Biosciences in a research report on Thursday, October 24th. They issued a “buy” rating and a $50.00 price objective for the company. Two analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $53.67.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.